Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2021
Diagnostic Performance of
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 221 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-center, Open-label, Single Arm Phase III Clinical Trial for the Diagnostic Efficacy Assessment and Safety Evaluation by [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer
A Two Center Phase 2 Trial of 61Cu-noDAGa-PSMA I&T (61Cu-NU101) for Patients With Prostate Cancer
Who cites it
221 citing papers in PubMed, 6 syntheses or guidelines pooled it, 358 citations in OpenAlex.
- PSMA PET/CT imaging for biochemical recurrence in prostate cancer: can it replace conventional imaging and guide salvage therapy?Annals of nuclear medicine · 2026Pooled it
- PSMA PET-guided intensification of postprostatectomy salvage radiotherapy for prostate cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A Systematic Review and Metaanalysis.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Pooled it
- Effect ofFrontiers in medicine · 2024Pooled it
- Detection of Biochemically Recurrent Prostate Cancer with [Tomography (Ann Arbor, Mich.) · 2023Pooled it
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.European journal of nuclear medicine and molecular imaging · 2023Guideline
- Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- An intra-patient contemporaneous comparison ofEuropean journal of nuclear medicine and molecular imaging · 2026Trial
- [18F]F-DCFPyL PET/MRI radiomics for intraprostatic prostate cancer detection and metastases prediction using whole-gland segmentation.The British journal of radiology · 2025Trial
- Imaging Efficacy of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Trial
- Imaging Efficacy of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Trial
- Safety, Dosimetry, and Feasibility of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Trial
- Trial
- Interreader and Intrareader Reproducibility ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Trial
- True-PositiveJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Trial
- PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Diagnostic accuracy of fully hybrid [European journal of nuclear medicine and molecular imaging · 2024Trial
- AnCurrent radiopharmaceuticals · 2024Trial
- [European journal of nuclear medicine and molecular imaging · 2023Trial
- Trial
161 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
20 authors at 14 institutions in 2 countries.
Funding
Abstract
purposeCurrent FDA-approved imaging modalities are inadequate for localizing prostate cancer biochemical recurrence (BCR). EXPERIMENTAL
designMen with rising PSA ≥0.2 ng/mL after prostatectomy or ≥2 ng/mL above nadir after radiotherapy were eligible. The primary endpoint was correct localization rate (CLR), defined as positive predictive value with an additional requirement of anatomic lesion colocalization between
resultsA total of 208 men with a median baseline PSA of 0.8 ng/mL (range: 0.2-98.4 ng/mL) underwent
conclusionsPerformance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.